November 2010
Alder to Present Data from Multiple Studies of ALD518 at Annual Meeting of the American College of Rheumatology
November 2010
Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
September 2010
FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
June 2010
New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism
June 2010
Alder Biopharmaceuticals to Present at Two Upcoming Investor Conferences
June 2010
Alder Biopharmaceuticals’ ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients
December 2009
Phase 1 Data on Alder Biopharmaceuticals’ ALD518 to be Presented at 5th Cachexia Conference
November 2009
Alder Biopharmaceuticals to Present at Piper Jaffray & Co. 21st Annual Healthcare Conference
November 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
August 2009
Alder Biopharmaceuticals Appoints Dr. Mark D. Young Senior VP Pharmaceutical Operations
June 2009
Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough
June 2009
Alder Presents Results from Phase I Trial of ALD518 in Advanced Cancer at ASCO Annual Meeting
January 2008
Alder Biopharmaceuticals Inc. Completes $40M Series C Financing
July 2006
Alder Biopharmaceuticals Inc. Completes Series B Financing
March 2006
Alder Biopharmaceuticals Appoints Clay B. Siegall, Ph.D. to Board
December 2005
Alder Biopharmaceuticals Inc. Forms Collaboration with Schering-Plough to Identify and Manufacture Antibody Therapeutics
November 2005
Alder Biopharmaceuticals Inc. Forms Research Collaboration with Seattle Genetics for Production of Antibodies
August 2005
Alder Biopharmaceuticals Inc. Raises $11.1M in Series A Financing
April 2004
Jeffrey T. L. Smith, M.D., Joins Alder Biopharmaceuticals Management Team
Alder to Present Data from Multiple Studies of ALD518 at Annual Meeting of the American College of Rheumatology
November 2010
Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
September 2010
FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
June 2010
New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism
June 2010
Alder Biopharmaceuticals to Present at Two Upcoming Investor Conferences
June 2010
Alder Biopharmaceuticals’ ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients
December 2009
Phase 1 Data on Alder Biopharmaceuticals’ ALD518 to be Presented at 5th Cachexia Conference
November 2009
Alder Biopharmaceuticals to Present at Piper Jaffray & Co. 21st Annual Healthcare Conference
November 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
August 2009
Alder Biopharmaceuticals Appoints Dr. Mark D. Young Senior VP Pharmaceutical Operations
June 2009
Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough
June 2009
Alder Presents Results from Phase I Trial of ALD518 in Advanced Cancer at ASCO Annual Meeting
January 2008
Alder Biopharmaceuticals Inc. Completes $40M Series C Financing
July 2006
Alder Biopharmaceuticals Inc. Completes Series B Financing
March 2006
Alder Biopharmaceuticals Appoints Clay B. Siegall, Ph.D. to Board
December 2005
Alder Biopharmaceuticals Inc. Forms Collaboration with Schering-Plough to Identify and Manufacture Antibody Therapeutics
November 2005
Alder Biopharmaceuticals Inc. Forms Research Collaboration with Seattle Genetics for Production of Antibodies
August 2005
Alder Biopharmaceuticals Inc. Raises $11.1M in Series A Financing
April 2004
Jeffrey T. L. Smith, M.D., Joins Alder Biopharmaceuticals Management Team
